Providence Capital Advisors’s Fate Therapeutics FATE Stock Holding History

Providence Capital Advisors’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$165	Buy	+61	New	+$113	﹤0.01%	380
2024 Q4	–	Sell	-61	Closed	-$214	–	181
2024 Q3	$214	Hold	61	–	–	﹤0.01%	346
2024 Q2	$200	Hold	61	–	–	﹤0.01%	348
2024 Q1	$448	Hold	61	–	–	﹤0.01%	329
2023 Q4	$228	Hold	61	–	–	﹤0.01%	329
2023 Q3	$129	Hold	61	–	–	﹤0.01%	346
2023 Q2	$290	Hold	61	–	–	﹤0.01%	303
2023 Q1	$348	Hold	61	–	–	﹤0.01%	298
2022 Q4	$615	Hold	61	–	–	﹤0.01%	275
2022 Q3	$1K	Hold	61	–	–	﹤0.01%	298
2022 Q2	$2K	Sell	61 -17	-22%	-$469	﹤0.01%	261
2022 Q1	$3K	Buy	78 +17	+28%	+$658	﹤0.01%	304
2021 Q4	$4K	Hold	61	–	–	﹤0.01%	277
2021 Q3	$4K	Hold	61	–	–	﹤0.01%	253
2021 Q2	$5K	Hold	61	–	–	﹤0.01%	253
2021 Q1	$5K	Sell	61 -30	-33%	-$2.87K	﹤0.01%	221
2020 Q4	$8K	Buy	+91	New	+$5.65K	﹤0.01%	227

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Providence Capital Advisors's FATE Position: Q2 2026 in Review

Providence Capital Advisors opened a new position in Fate Therapeutics (FATE) in Q2 2026: 61 shares worth $165. The stake represents ﹤0.01% of the portfolio and ranks #380 among its holdings. This is a return to the name: Providence Capital Advisors previously reported a position in FATE as recently as Q3 2024.

Providence Capital Advisors first reported a position in FATE in Q4 2020 and has held it in 17 quarters since. The position peaked at $8K in Q4 2020. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

Providence Capital Advisors held 61 shares of Fate Therapeutics worth $165 as of Q2 2026.
Fate Therapeutics was a new Providence Capital Advisors position in Q2 2026.
Fate Therapeutics made up ﹤0.01% of Providence Capital Advisors's portfolio in Q2 2026, its #380 holding.
Providence Capital Advisors first reported a position in Fate Therapeutics in Q4 2020 and has held it in 17 quarters since.
Providence Capital Advisors's Fate Therapeutics position peaked at $8K in Q4 2020.
156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Providence Capital Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.